Extracellular vesicles as biomarkers in liver diseases: a clinician's point of view

S Thietart, PE Rautou - Journal of hepatology, 2020 - Elsevier
Extracellular vesicles are membrane-bound vesicles containing proteins, lipids, RNAs and
microRNAs. They can originate from both healthy and stressed cells, and provide a …

Forty years of molecular diagnostics for infectious diseases

JE Schmitz, CW Stratton, DH Persing… - Journal of Clinical …, 2022 - Am Soc Microbiol
Nearly 40 years have elapsed since the invention of the PCR, with its extremely sensitive
and specific ability to detect nucleic acids via in vitro enzyme-mediated amplification. In turn …

Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men

BM Nijmeijer, J Koopsen, J Schinkel… - Journal of the …, 2019 - Wiley Online Library
Abstract Introduction Hepatitis C virus (HCV) is a major public health threat. Although the
recent availability of highly effective directly acting antivirals created optimism towards HCV …

[HTML][HTML] Assessing solid organ donors and monitoring transplant recipients for human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection—US …

JM Jones - MMWR. Recommendations and Reports, 2020 - cdc.gov
The recommendations in this report supersede the US Public Health Service (PHS)
guideline recommendations for reducing transmission of human immunodeficiency virus …

[PDF][PDF] Molecular docking and dynamics simulations reveal the potential of anti-HCV drugs to inhibit COVID-19 main protease

AA Al-Karmalawy, R Alnajjar, M Dahab… - Pharmaceutical …, 2021 - ps.tbzmed.ac.ir
Background: Drug repurposing is the fastest effective method to provide treatment for
coronavirus disease (COVID-19). Drugs that targeting a closely related virus with similar …

Hepatitis C guidance 2023 update: american association for the study of liver diseases–infectious diseases society of america recommendations for testing, managing …

D Bhattacharya, A Aronsohn, J Price… - Clinical Infectious …, 2023 - academic.oup.com
Abstract The Infectious Diseases Society of America and the American Association for the
Study of Liver Diseases have collaboratively developed evidence-based guidance …

Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis

Y Tahata, H Hikita, S Mochida, N Enomoto… - Journal of …, 2022 - Springer
Background Direct-acting antiviral (DAA) therapy enables a high rate of sustained virologic
response (SVR) in patients with hepatitis C virus associated cirrhosis. However, the impact …

Drug‐drug interactions with candidate medications used for COVID‐19 treatment: an overview

H Rezaee, F Pourkarim… - Pharmacology …, 2021 - Wiley Online Library
Drug‐drug interaction (DDI) is a common clinical problem that has occurred as a result of the
concomitant use of multiple drugs. DDI may occur in patients under treatment with …

Complementing 16S rRNA gene amplicon sequencing with total bacterial load to infer absolute species concentrations in the vaginal microbiome

FA Tettamanti Boshier, S Srinivasan, A Lopez… - Msystems, 2020 - Am Soc Microbiol
Whereas 16S rRNA gene amplicon sequencing quantifies relative abundances of bacterial
taxa, variation in total bacterial load between samples restricts its ability to reflect absolute …

Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study

Y Tahata, H Hikita, S Mochida, N Kawada… - Journal of …, 2021 - Springer
Background Real-world data on the efficacy and safety of sofosbuvir plus velpatasvir
(SOF/VEL) treatment for patients with hepatitis C virus (HCV)-related decompensated …